This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NBI-77860

Neurocrine Biosciences, Inc.

Drug Names(s): GSK561679, verucerfont

Description: GSK561679 is a Corticotropin Releasing Factor R1 (CRF1) receptor antagonist.

Deal Structure: Neurocrine and GSK
In July 2001, Neurocrine and GSK entered into a worldwide research, development and commercialization agreement for CRF1 receptor antagonists to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression, and IBS.

In September 2012, Neurocrine and GSK entered into a Termination Agreement pursuant to which the parties have mutually agreed to terminate that certain Collaboration and License Agreement dated July 20, 2001 related to the research, development and commercialization of corticotropin releasing factor (CRF) products for psychiatric, neurological and gastrointestinal diseases.

Pursuant to the terms of the Termination Agreement, GSK assigned to the Company, or granted the Company an exclusive worldwide royalty-free license to, all patent rights created from the sponsored research portion of the Collaboration Agreement, including all related regulatory filings and approvals. GSK also assigned to the...See full deal structure in Biomedtracker


NBI-77860 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug